FDA Cracks Down Hard on Compounded GLP-1 Sellers
The FDA just sent warning letters to 30 companies selling knockoff GLP-1s and says they're ready to take serious legal action. If you've been using compounded versions, here's what you need to know.
FDA Gets Serious About Compounded GLP-1 Crackdown
The FDA isn't messing around anymore. They just announced they're planning legal action against companies selling non-FDA-approved GLP-1 medications – and they've already fired the first shot by sending warning letters to 30 telehealth companies.
Here's what's happening: Companies like Hims & Hers have been mass-marketing compounded versions of popular drugs, claiming they're just as good as the real deal. But the FDA says that's misleading advertising, plain and simple. These compounded drugs haven't gone through the same safety and quality checks as Wegovy or Zepbound.
The agency is threatening seizures and injunctions if companies don't comply. That's lawyer-speak for "we'll shut you down and take your stuff."
What This Means for Your Wallet and Health
I get it – compounded versions have been way cheaper and easier to get. But there's a reason the FDA is stepping in now. The drug shortages that made compounded versions legally acceptable? Those are mostly resolved.
Without those shortages, compounded GLP-1s exist in a legal gray area. The FDA's concern isn't just about paperwork – it's about knowing what you're actually putting in your body. Quality control varies wildly between compounding pharmacies.
Meanwhile, New Options Are Coming
While all this regulatory drama unfolds, there's some potentially good news on the horizon. Novo Nordisk's experimental triple-action drug UBT251 just showed impressive results in Phase 2 trials – we're talking 19.7% average weight loss over 24 weeks.
This new drug targets three different pathways (GLP-1, GIP, and glucagon) instead of just one or two like current medications. It's designed to compete with Eli Lilly's similar triple-action drug that's in development.
Oral GLP-1s Are Actually Here Now
Speaking of new options, Novo Nordisk launched their oral GLP-1 pills on January 5th, and they're already popular – 170,000 prescriptions in just three weeks. The weight loss results aren't quite as strong as the injections (13% vs 15-16%), but plenty of people prefer swallowing a pill to giving themselves shots.
You'd start at 1.5mg and potentially work up to 25mg, depending on how you respond and what side effects you experience.
Bottom Line
If you're currently using a compounded GLP-1, don't panic and stop cold turkey – but do start planning. Talk to your doctor about transitioning to an FDA-approved option. Yes, it'll probably cost more, but you'll know exactly what you're getting. The compounded market was helpful during the shortages, but those days are ending whether we like it or not.
